Livzon Pharmaceutical Group

Livzon Pharmaceutical Group, formally Livzon Pharmaceutical Group Inc. (丽珠医药集团股份有限公司), is a Chinese pharmaceutical group whose activities span research and development, manufacturing, and commercialization. The company describes itself as a large, integrated pharmaceutical group and is listed on both the Shenzhen Stock Exchange and the Hong Kong Stock Exchange. Its A-share code is 000513.SZ and its H-share code is 01513.HK. The company’s stated headquarters address is in Jinwan District, Zhuhai, Guangdong, China. Livzon’s portfolio and development work cover chemical medicines, biologics, and traditional Chinese medicine. Its chemical-medicine priorities include innovative drugs, complex formulations with high technical barriers, and products with clinical value. The company identifies gastrointestinal disease, psychiatry, assisted reproduction, and anti-infective treatment among its areas of focus, alongside autoimmune, metabolic, cardiovascular, and cerebrovascular diseases. It also describes long-acting microsphere formulations as a core technical area. In biologics, its stated interests include autoimmune disease, infectious-disease prevention, and assisted reproduction; the company says it has established research platforms and commercial manufacturing capacity for recombinant protein medicines and vaccines. Its traditional Chinese medicine portfolio includes innovative medicines, classical formulas, and health products. Products highlighted on the company website include the acid-suppressing medicine Ilaprazole (壹丽安), long-acting microsphere products such as Aripiprazole microspheres (阿丽唯) and Triptorelin acetate microspheres (维宝宁), fertility-related medicines, Tocilizumab injection, and Shenqi Fuzheng Injection (参芪扶正注射液). The company also presents selected products for international business, including injectable gonadotropin products, Leuprorelin acetate microspheres, mouse nerve growth factor, and Ilaprazole sodium for injection. These product listings indicate a business that combines domestic product commercialization with an international sales network; the supplied material does not specify the precise countries served. Livzon says it has built research infrastructure including a nationally recognized enterprise technology center, a national-local joint engineering research center for long-acting microspheres, a national engineering technology research center for modernization of traditional Chinese medicine, and a postdoctoral research workstation. The company states that its mission is to put patients’ quality of life first and its vision is to become a leading company in the pharmaceutical industry. Its website reports 2025 revenue and net profit, but those figures are not repeated here because they are not needed to describe the brand’s identity and scope.

Livzon Pharmaceutical Group is presented in the supplied company materials as an integrated pharmaceutical business spanning research, manufacturing, and commercialization. The available evidence does not establish its founding date, founders, or early corporate history, so no specific origin story or founding milestone can be assigned. The company’s current profile is built around three broad product areas: chemical medicines, biologics, and traditional Chinese medicine. Its company introduction describes a strategy that combines the development of innovative medicines with complex formulations and products intended to address clinical needs. The stated therapeutic areas include gastrointestinal disease, psychiatry, assisted reproduction, and anti-infective treatment, as well as autoimmune, metabolic, cardiovascular, and cerebrovascular diseases. The company identifies long-acting microsphere technology as a significant development capability. It says that it established a national-local joint engineering research center for long-acting microspheres and that products including Triptorelin acetate microspheres and Aripiprazole microspheres have reached the market. In chemical medicines, Livzon highlights Ilaprazole as an independently developed innovative drug and presents tablet and injectable forms among its key products. In biologics, Livzon describes a focus on autoimmune conditions, infectious-disease prevention, and assisted reproduction. It says that its capabilities include platforms for early drug discovery, druggability assessment, development and quality evaluation of large-molecule protein medicines, and vaccine technology, together with commercial manufacturing facilities for recombinant protein medicines and vaccines. Website product and news listings include fertility-related products, Tocilizumab injection, and vaccine offerings. The company’s traditional Chinese medicine business is described as spanning innovative Chinese medicines, classical formulas, and health products. Livzon says it has more than twenty marketed exclusive traditional Chinese medicine products and names Shenqi Fuzheng Injection and antiviral granules among its offerings. The supplied evidence does not independently establish each product’s current regulatory or commercial status beyond the company’s own descriptions and listings. Livzon reports having established several research institutions and capabilities, including a nationally recognized enterprise technology center, a national-local joint engineering research center for long-acting microspheres, a national engineering technology research center for modernization of traditional Chinese medicine, and a postdoctoral research workstation. The company also states that its projects have received national and provincial-level science and technology awards. These are company-reported descriptions; the evidence provided does not supply dates for the establishment of the facilities or awards. Livzon is listed on the Shenzhen and Hong Kong stock exchanges. The company introduction identifies its A-share and H-share codes and presents the business as a listed pharmaceutical group. Its website also provides sections for investor relations, international business, and international product offerings, indicating that its company-facing structure extends beyond domestic product information. The supplied evidence does not identify a parent company, controlling owner, founder, or current executives. The company’s stated mission is to put patients’ quality of life first, and its stated vision is to be a leading company in the pharmaceutical industry. The official homepage lists recent product and pipeline announcements, including the approval of its recombinant human follicle-stimulating hormone injection in 2026 and clinical-development updates. These dated items are recorded as company-reported announcements; the supplied materials do not provide a fuller chronology of the company’s earlier development.

• Recombinant human follicle-stimulating hormone injection Lizyoubao reported approved

  [1]丽珠医药集团股份有限公司-销售为一体的综合医药集团公司livzon.com.cn
• Marketing application for IL-17A/F dual-targeting drug accepted

  [1]丽珠医药集团股份有限公司-销售为一体的综合医药集团公司livzon.com.cn
• First patient dosed in Phase III trial of JP-1366 for injection

  [1]丽珠医药集团股份有限公司-销售为一体的综合医药集团公司livzon.com.cn

An integrated, publicly listed pharmaceutical group with a diversified portfolio spanning chemical medicines, biologics, and traditional Chinese medicine, and an emphasis on research-led innovation and complex formulations.

• Chemical drugs; acid suppression therapy

  Ilaprazole enteric-coated tablets and Ilaprazole sodium for injection (壹丽安)

• Long-acting microsphere formulations

  Aripiprazole microspheres for injection (阿丽唯)

• Long-acting microsphere formulations

  Triptorelin acetate microspheres for injection (维宝宁)

• Biologics; assisted reproductive drugs

  Recombinant human follicle-stimulating hormone injection (丽优宝)

• Biologics

  Tocilizumab injection (安维泰)

• Traditional Chinese Medicine

  Shenqi Fuzheng Injection

• 2023

  Source

• 2011

  Source

Read more

• Strategic focus on innovation and complex formulationsOther

  Source

• 2020-10-15

  ZSenith Peptide and Livzon agree to develop peptide drugs[7]中晟全肽与丽珠医药达成多肽新药合作开发协议hn.rednet.cn

  Reported: 2020-10-15

  Hunan ZSenith Peptide Biochemical Co. and Livzon Pharmaceutical Group agreed to collaborate on new-drug development. ZSenith Peptide will use its peptide technology and screening platforms to identify lead compounds in areas including digestive diseases and oncology, while Livzon will use its long-acting microsphere technology to commercialize products. Financial terms were not disclosed.

• 2020-06-30

  Lizhu Pharmaceutical appoints board members and committee members[8]丽珠医药委任董事及委员会成员finance.sina.com.cn

  Reported: 2020-06-30

  At its 2020 third extraordinary general meeting, Lizhu Pharmaceutical appointed Bai Hua and Yu Xiong as independent non-executive director and non-executive director, respectively. The source also reports committee appointments made at the first meeting of the tenth board.

• 2019-09-27

  Lizhu Group executive resigns[9]丽珠集团董事及高级管理人员辞职finance.sina.com.cn

  Reported: 2019-09-27

  Lizhu Pharmaceutical Group said Fu Daotian resigned as an executive director and vice president, as well as from all positions at its subsidiaries, effective when his resignation letter was delivered to the board on September 27, 2019.

1. 1丽珠医药集团股份有限公司-销售为一体的综合医药集团公司livzon.com.cn
2. 2公司简介-丽珠医药集团股份有限公司livzon.com.cn
3. 3重点产品-重点产品-丽珠医药集团股份有限公司livzon.com.cn
4. 4国际重点产品-国际重点产品-丽珠医药集团股份有限公司livzon.com.cn
5. 5子公司行贿被禁入上海药械市场两年p5w.net
6. 6审计署指丽珠制药通过员工咨询公司套取资金用于药品公关nbd.com.cn
7. 7中晟全肽与丽珠医药达成多肽新药合作开发协议hn.rednet.cn
8. 8丽珠医药委任董事及委员会成员finance.sina.com.cn
9. 9丽珠集团董事及高级管理人员辞职finance.sina.com.cn
10. 10丽珠集团：关于公司董事及高级管理人员辞职的公告finance.sina.com.cn